Broussonetia Papyrifera Pollen

Dosage for Broussonetia Papyrifera Pollen is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity. There is no 'standard' dose for all patients.

Skin Testing Dosage

• Prick/Scratch Testing: Usually performed using a concentrated glycerinated extract (e.g., 1:20 w/v). A single drop is applied to the skin, and a sterile lancet is used to prick the epidermis.
• Intradermal Testing: If prick tests are negative, intradermal testing may be performed using a much more dilute aqueous solution (e.g., 100 PNU/mL to 1,000 PNU/mL). Usually, 0.02 mL to 0.05 mL is injected to create a small bleb.

Immunotherapy Dosage (SCIT)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:10,000 w/v dilution). Injections are given 1-2 times per week, with the dose increasing by 50% to 100% each time, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'top dose' or 'maintenance dose' is reached (often 0.5 mL of a 1:100 or 1:20 w/v concentration), the interval between injections is increased to every 2-4 weeks. Maintenance therapy usually continues for 3 to 5 years.

Broussonetia Papyrifera Pollen is approved for use in children, typically those aged 5 years and older. The dosing principles for children are identical to those for adults, as the dose is based on immunological sensitivity rather than body weight. However, extra caution is required in younger children who may be unable to communicate early symptoms of a systemic reaction.

Renal Impairment

No specific dose adjustments are required for patients with renal impairment, as the extract is not cleared by the kidneys. However, the patient's overall health status should be considered.

Hepatic Impairment

No dose adjustments are required for hepatic impairment. The metabolic processing of the proteins occurs at the cellular level in the immune system.

Elderly Patients

Elderly patients may have a higher prevalence of underlying cardiovascular disease. Because the treatment for a systemic reaction (epinephrine) can stress the heart, the risk-benefit ratio must be carefully weighed in patients over 65.

Broussonetia Papyrifera Pollen must ONLY be administered by a healthcare professional in a clinical setting equipped to treat anaphylaxis. It is never for self-administration at home.

• Administration Route: Subcutaneous injection (usually in the posterior aspect of the upper arm).
• Preparation: The vial should be inspected for particulate matter or discoloration. Vials should be kept refrigerated at 2°C to 8°C (36°F to 46°F).
• Timing: Injections should be avoided if the patient is currently experiencing an acute asthma flare or has a fever.
• Post-Injection Observation: Patients MUST remain in the clinic for at least 30 minutes following every injection to monitor for signs of a systemic reaction.

If a dose is missed during the build-up phase, the next dose may need to be reduced depending on the length of the delay:

• Delay of 1-7 days: Proceed with the scheduled increase.
• Delay of 8-14 days: Repeat the last tolerated dose.
• Delay of >14 days: Reduce the dose by one or more increments.

Your allergist will follow a specific 'gap protocol' to ensure safety.

An 'overdose' in the context of immunotherapy usually refers to an injection given at a concentration higher than the patient's current tolerance level. This can lead to severe systemic reactions or anaphylaxis.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, drop in blood pressure, or loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and oxygen. Emergency medical services (EMS) must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance, as this increases the risk of reactions.

Local reactions at the site of injection are extremely common and are often considered a normal part of the body's response to the allergen.

• Local Swelling (Wheal): A raised, firm area at the injection site. This typically appears within minutes and may last for several hours.
• Erythema (Redness): Redness surrounding the injection site, which may feel warm to the touch.
• Pruritus (Itching): Intense itching at the site of the injection. This can usually be managed with topical hydrocortisone or oral antihistamines.
• Tenderness: The arm may feel sore or heavy for 24-48 hours following the injection.

These reactions are slightly more concerning and may indicate that the dose is approaching the patient's limit of tolerance.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter or extends beyond the joint (e.g., from the upper arm to the elbow). These may require a dose reduction or a slower build-up schedule.
• Fatigue: Some patients report feeling unusually tired for several hours after their immunotherapy session.
• Mild Nasal Congestion: A slight increase in hay fever symptoms shortly after the injection.

• Systemic Non-Life-Threatening Reactions: Generalized hives (urticaria) that appear on parts of the body away from the injection site, or mild wheezing that responds quickly to a bronchodilator.
• Lymphadenopathy: Swelling of the lymph nodes in the axilla (armpit) on the side of the injection.

> Warning: Stop taking Broussonetia Papyrifera Pollen and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Upper Airway Obstruction: Feeling of 'tightness' in the throat, difficulty swallowing, or a change in voice (hoarseness).
• Lower Airway Obstruction: Severe wheezing, chest tightness, or shortness of breath (dyspnea).
• Cardiovascular Collapse: Dizziness, lightheadedness, rapid or weak pulse, and a sudden drop in blood pressure (hypotension).
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after an injection.
• Angioedema: Significant swelling of the lips, tongue, or around the eyes.

There are no known long-term 'toxic' side effects of Broussonetia Papyrifera Pollen. Because it is a natural protein, it does not accumulate in organs or cause chronic diseases. The primary long-term 'effect' is the desired one: a significant reduction in allergy symptoms and a decreased risk of developing new sensitizations or progressing from allergic rhinitis to asthma. Some studies suggest that the benefits of immunotherapy can persist for several years after the treatment is discontinued.

While specific 'Black Box' labels vary by manufacturer, all allergenic extracts carry a prominent warning regarding Anaphylaxis.

• Summary of Warning: This product can cause severe, life-threatening systemic reactions, including anaphylaxis. It must only be administered in a setting where emergency equipment and personnel trained in treating anaphylaxis are immediately available. Patients with unstable asthma are at a significantly higher risk for fatal reactions. Patients must be observed for at least 30 minutes post-injection.

Report any unusual symptoms to your healthcare provider, even if they seem minor at first. Early detection of a systemic reaction is key to safe treatment.

Broussonetia Papyrifera Pollen is a potent biological agent. Its use is restricted to patients with a clear diagnosis of IgE-mediated allergy. It is not a general 'tonic' or treatment for non-allergic conditions. The most critical safety factor is the patient's current health status on the day of the injection.

No FDA black box warnings are officially listed for Broussonetia Papyrifera Pollen in the same format as small-molecule drugs, but it carries the standard 'General Warning' for all allergenic extracts regarding the risk of severe systemic reactions. The primary risk is sudden-onset anaphylaxis, which can occur even in patients who have previously tolerated the same dose.

• Anaphylaxis Risk: This is the primary concern. Risk factors include a high level of sensitivity, rapid dose escalation, and injections given during the peak of the pollen season.
• Asthma Stability: Patients with asthma MUST have their condition well-controlled (e.g., FEV1 > 80% of predicted) before receiving an injection. An injection given during an asthma flare can trigger a fatal bronchospasm.
• Epinephrine Availability: Patients undergoing immunotherapy are strongly encouraged to carry an epinephrine auto-injector (e.g., EpiPen) at all times, especially on the day of their injection.
• Injection Technique: Accidental intravenous injection can cause immediate, severe anaphylaxis. The healthcare provider must always aspirate before injecting to ensure the needle is not in a blood vessel.

• Wait Time: A strict 30-minute post-injection observation period is mandatory. Most fatal reactions occur within this window.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before the injection to ensure lung function is stable.
• Reaction Log: Patients should keep a log of any local reactions (size and duration) to help the doctor adjust the next dose.

Most patients can drive after the 30-minute observation period. However, if a patient experiences significant fatigue or takes a sedating antihistamine to treat a local reaction, they should avoid driving until they feel fully alert.

Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can cause vasodilation, which may potentially increase the rate of allergen absorption or mask the early symptoms of a systemic reaction.

Immunotherapy is typically discontinued if:

1. 1The patient experiences a life-threatening systemic reaction.
2. 2The patient is unable to adhere to the schedule or the 30-minute wait time.
3. 3There is no clinical improvement after 12-24 months of maintenance therapy.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Broussonetia Papyrifera Pollen.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These are strictly contraindicated in most immunotherapy protocols. Beta-blockers can make a systemic reaction more severe and, more importantly, they can make the patient's reaction resistant to the life-saving effects of epinephrine. If a patient requires a beta-blocker for a heart condition, immunotherapy is usually avoided.

• ACE Inhibitors (e.g., Lisinopril): Some evidence suggests that ACE inhibitors may increase the risk of severe systemic reactions or interfere with the body's compensatory mechanisms during anaphylaxis.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effect of epinephrine used to treat a reaction, leading to a dangerous spike in blood pressure.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can interfere with the management of an anaphylactic event.

• Other Immunotherapy: If a patient is receiving multiple types of immunotherapy (e.g., for dust mites and pollen), the injections should ideally be given in different arms, and the doses should be carefully coordinated to avoid 'summation' effects.
• Antihistamines: While often used to manage side effects, antihistamines can mask the early 'warning signs' of a systemic reaction (like itching or hives), which might lead to the healthcare provider giving a higher dose than is safe.

• Cross-Reactive Foods: Some patients with Paper Mulberry allergy may experience Oral Allergy Syndrome (OAS) when eating certain fruits (like mulberry or figs). While not a direct 'drug-food interaction,' eating these foods around the time of an injection might theoretically lower the threshold for a reaction.
• Large Meals: Avoid eating a very heavy or spicy meal immediately before an injection, as this can sometimes cause gastrointestinal symptoms that mimic the early stages of anaphylaxis.

There are no well-documented interactions between Broussonetia Papyrifera Pollen and herbal supplements. However, supplements that have 'immune-boosting' claims (like Echinacea) should be used with caution as they could theoretically interfere with the immune-modulating goals of immunotherapy.

• Skin Tests: Broussonetia Papyrifera Pollen is the substance used for the test. However, other drugs can interfere with the results of the skin test. Patients must stop taking antihistamines (usually 3-7 days prior) and H2 blockers (like famotidine) before testing, as these will cause a false-negative result.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any new medications for blood pressure or heart health.

• Uncontrolled Asthma: Patients with severe or unstable asthma (FEV1 persistently below 70-80% of predicted) must never receive Broussonetia Papyrifera Pollen. The risk of a fatal bronchospasm during a systemic reaction is too high.
• Recent Myocardial Infarction (Heart Attack): Patients who have had a recent heart attack or have unstable angina cannot tolerate the physiological stress of a systemic reaction or the epinephrine required to treat it.
• Severe Immunodeficiency: Patients with compromised immune systems may not respond to the therapy and are at higher risk for complications.
• Malignancy: Active cancer is generally a contraindication, as the immune system is already under significant stress.

• Beta-Blocker Therapy: As mentioned, this is a major safety concern. If the beta-blocker cannot be switched to another class of drug, immunotherapy is usually withheld.
• Pregnancy (Initiation): Immunotherapy should never be started during pregnancy due to the risk of anaphylaxis causing fetal hypoxia (lack of oxygen).
• Young Children (<5 years): Often contraindicated because they cannot communicate early symptoms of a reaction.

Patients allergic to Broussonetia Papyrifera Pollen may show cross-sensitivity to other members of the Moraceae family, including:

• Morus alba (White Mulberry)
• Morus rubra (Red Mulberry)
• Ficus species (Figs)
• Cannabis sativa (Hemp/Marijuana) - due to taxonomic relation.

> Important: Your healthcare provider will evaluate your complete medical history and current lung function before prescribing Broussonetia Papyrifera Pollen.

Pregnancy Category C (standard for allergenic extracts).

• Risk Summary: There are no adequate and well-controlled studies in pregnant women. However, the primary risk is not the extract itself, but the potential for anaphylaxis in the mother, which can lead to uterine contractions, placental abruption, or fetal death due to oxygen deprivation.
• Clinical Practice: It is generally recommended not to start immunotherapy during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, many allergists will continue the treatment at the same or a slightly reduced dose, as the risk of a reaction is much lower during the maintenance phase.

It is generally considered safe to continue Broussonetia Papyrifera Pollen immunotherapy while breastfeeding. The large protein molecules in the extract are not expected to pass into breast milk in any significant quantity, and even if they did, they would be digested by the infant's stomach. There is no evidence of harm to the nursing infant.

• Approved Age: Generally safe for children 5 years and older. Use in children under 5 is rare because of the difficulty in monitoring for systemic reactions and the psychological trauma of frequent injections.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development.
• Disease Modification: One of the primary benefits in children is the 'preventive' effect—immunotherapy may prevent the 'allergic march' (the progression from rhinitis to asthma).

• Cardiovascular Risk: Patients over 65 are at higher risk for underlying heart disease. The use of epinephrine to treat a reaction in this age group carries a higher risk of arrhythmia or myocardial infarction.
• Reduced Reserve: Elderly patients may have less pulmonary reserve to survive a severe systemic reaction.
• Polypharmacy: Increased likelihood of taking interacting medications like beta-blockers or ACE inhibitors.

No dosage adjustments are needed. The extract components are processed by the immune system and do not rely on renal excretion. However, patients with chronic kidney disease should be monitored for overall physiological stability.

No dosage adjustments are needed. The liver does not play a primary role in the clearance of injected allergenic proteins.

> Important: Special populations require individualized medical assessment and a careful weighing of the risks of the treatment versus the benefits of allergy relief.

Broussonetia Papyrifera Pollen acts as an immunomodulator. The primary goal is to shift the immune system from a state of hypersensitivity to a state of hyposensitivity.

• Early Phase: Subcutaneous administration leads to the capture of allergens by dendritic cells.
• T-Cell Response: These cells present allergen peptides to naive T-cells, promoting the development of T-regulatory (Treg) cells instead of Th2 cells.
• Cytokine Profile: Tregs produce IL-10 and TGF-beta, which suppress the allergic inflammation.
• B-Cell Response: B-cells are induced to produce IgG4 instead of IgE. IgG4 acts as a 'decoy,' binding the pollen proteins before they can reach the IgE on mast cells.

• Dose-Response: There is a clear dose-response relationship; higher maintenance doses are generally more effective but carry a higher risk of side effects.
• Onset of Effect: Clinical improvement is usually not seen for 3-6 months (during the build-up phase). Full benefits often take 12 months.
• Duration: The effects are long-lasting, often persisting for years after a 3-5 year course of treatment.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous injection for local immune uptake) |

| Protein Binding | N/A (Interacts with antibodies and cell receptors) |

| Half-life | Variable (Proteins are degraded within hours to days) |

| Tmax | 1-2 hours (for systemic absorption of small components) |

| Metabolism | Proteolysis by antigen-presenting cells |

| Excretion | Cellular degradation; minimal renal/fecal excretion |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides derived from the pollen of Broussonetia papyrifera.
• Solubility: Soluble in aqueous buffers; often provided in 50% glycerin for stability.
• Potency: Measured in Protein Nitrogen Units (PNU), where 1 PNU = 0.00001 mg of protein nitrogen.

Broussonetia Papyrifera Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It is part of the broader category of Allergenic Extracts used for immunotherapy and diagnostic testing.